Effect of CoQ10 Administration to Psoriatic Iraqi Patients on Biological Therapy Upon Severity Index (PASI) and Quality of Life Index (DLQI) Before and After Therapy.

Main Article Content

Ghadah Ali Al-Oudah
Ahmed Salih Sahib
Mohammed K. Al-Hattab
Ali Ameer Al-Ameedee


PASI, DLQI, CoQ10, Psoriasis, Biological Therapy.


Psoriasis is a medical condition in which the skin of the body is affected in a multisytemic level. Patients with moderate to severe psoriasis have a considerably reduced quality of life as a result of their disease. For morphological indicators, The Psoriasis Area Severity Index (PASI) test is one of the methods that have been tested for indicating the severity of the illness.An imbalance between pro-oxidants and antioxidants in our bodies causes oxidative stress to play a crucial role in the pathophysiology of chronic inflammatory diseases like psoriasis(1).It has been considered that antioxidant treatment can turn out to be an effective therapeutic option. The goal of this clinical investigation was to see if there was a link between the percentage change in quality of life and the clinical severity of psoriasis during a 12-week period among Iraqi psoriatic patients. Over the course of three months, 24 psoriatic patients (9 females and 15 males) ranging in age from 17 to 72 years old participated in a prospective double-blind clinical experiment. Two groups of participants were formed. A biological medicine (Adalimumab) and a placebo was given to group A (n=11), while group B (n=13) received 100 mg CoQ10 adjuvant therapy in addition to the biological medication already provided. The Psoriasis Area and Severity Index (PASI) and the Dermatology Life Quality Index (DLQI) were used to examine patients (DLQI). From treatment, with both biological and adjuvant CoQ10 therapy, showed a substantial association between the PASI and the DLQI (p value = 0.000132). After three months of therapy, the mean SD of PASI score for all patients was 20.88  7.15, with a 67.48 22.25032 percent improvement change. The mean SD of the DLQI score at baseline was 12.5 4.71, with a change of 56.13 20.15 percent following treatment. After therapy with a biological medication, there was a favorable association between the PASI and the DLQI (p>0.05). This indicates that therapy with a biological medication with daily administration of 100 mg CoQ10 supplements to psoriatic patients for 12 weeks improved the correlation between the PASI and DLQI.

Abstract 140 | pdf Downloads 74 PDF Downloads 137 XML Downloads 63 HTML Downloads 888


1.Guarneri et.al. Therapies with Antioxidant Potential in Psoriasis, Vitiligo, and,Lichen Planus. Review, Antioxidants 2021 ,10, 1087. https://doi.org/10.3390/antiox10071087.
2. Lima et al.. Psoriasis prevalence among the 2009 AAD National,Melanoma/Skin Cancer Screening Program participants. Journal of the European Academy of Dermatology and Venereology. 2012 DOI: 10.1111/j.1468-3083.2012.04531.
3.Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, et al. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007;156(2):258-62. www.thelancet.com Vol 370 July 21, 2007 Lancet 2007
4. Al-Sultany et al ( (2020): A-Sea. Assessment of serum zinc, copper and copper/zinc ratio in adult patients with psoriasis. Annals of Tropical Medicine & Public Health S391 2020;Vol. 23 (I).
5. Sojević Timotijević et al.. The Impact of Changes in Psoriasis Area and,Severity Index by Body Region on Quality of Life,in Patients with Psoriasis. Acta Dermatovenerol Croat. 2017;25(3):215-222:215-22 Clinical artical.
6. Silva MFP et.al. . Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment. Journal of Dermatology & Dermatologic Surgery. 2013,DOI: http://dx.doi.org/10.1590/abd1806-4841.20132052.
7.T.FREDRIKSSON and PETTERSSON. Severe Psoriasis -Oral Therapy With A New Retioid. Dermtologica. 1978 157:238-44.
8.Pariser DM. National Psoriasis Foundation,Clinical Consensus on Disease Severity. Arch Dermatol 2007;. 2007;143:239-242:239-42.
9. Al Raddadi, A. et.al. Psoriasis: Correlation between severity index (PASI) and quality of life index (DLQI) based on the type of treatment. Journal of Dermatology & Dermatologic Surgery. 2015, http://dx.doi.org/10.1016/j.jdds.2015.05.002
10.Finlay AY. Current severe psoriasis and the Rule of Tens. review article, British Journal of Dermatology 2005 2005;152:, pp861–7.
11.Winiarska-Mieczan A, Mieczan T, Wojcik G. Importance of Redox Equilibrium in the Pathogenesis of Psoriasis-Impact of Antioxidant-Rich Diet. Nutrients. 2020;12(6).
12.Al-Mokhtar et.al.. Leptin and Resistin Induce Oxidative Stress in Patients with Chronic Plaque Psoriatic. Journal of Pharmaceutical, Biological and Chemical Sciences · January 2017. 2017;8(1)(0975-8585):Page No. 135.
13.Sies B, and Dean P. Jones4. Oxidative Stress. Annu Rev Biochem 2017 2017;86:25.1–.34.
14. Y.Yang et.al... Reactive Oxygen Species in the Immune System. International Reviews of Immunology. 2013(0883-0185), DOI: 10.3109/08830185.2012.755176.
15.Zhou Q, Mrowietz U, Rostami-Yazdi M. Oxidative stress in the pathogenesis of psoriasis. Free Radic Biol Med. 2009;47(7):891-905.
16. Khmaladze et al.. Mannan induces ROS-regulated, IL-17A–dependent psoriasis arthritis-like disease in mice. IMMUNOLOGY AND INFLAMMATION. 2014;E3669–E3678, www.pnas.org/cgi/doi/10.1073/pnas.1405798111.
17.Kumar A, Kaur H, Devi P, Mohan V. Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther. 2009;124(3):259-68.
18.Battino M et.al. OXIDATIVE INJURY AND INFLAMMATORY PERIODONTAL DISEASES: THE CHALLENGE OF ANTI-OXIDANTS TO FREE RADICALS AND REACTIVE OXYGEN SPECIES. Critical Reviews in Oral Biology & Medicine. 1999;10(4): :458-76, DOI: 10.1177/10454411990100040301
19.Lebwohl M. Psoriasis. ,Seminar.. THE LANCET • Vol 361 • April 5, (9364):1197-204, 2003 • www.thelancet.com
20. F.SAMPOGNA et al.. Prevalence of symptoms experienced by patients with different clinical types of psoriasis. British Journal of Dermatology. 2004;151: 594–9. DOI: 10.1111/j.1365-2133.2004.06093
21. E. Mazzotti et al.. Psychometric Properties of the Dermatology Life Quality Index (DLQI) in 900 Italian Patients with Psoriasis. Acta Derm Venereol. 2005(0001-5555). DOI: 10.1080/00015550510032832
22.J.Bhosle M.et.al. Quality of life in patients with psoriasis. Health and Quality of Life Outcomes 2006, Review. doi:10.1186/1477-7525-4-35, http://www.hqlo.com/content/4/1/35
23.SOJEVIC. Identification of psoriatic patients at risk of high quality of life impairment. Japanese Dermatological Association. 2013;40:: 797–804.
24. Gelfand et al Determinants of quality of life in patients with psoriasis: A study from the US population. American Academy of Dermatology,. 2004;2004;51:(5):704-8.).
25. H.L. Richards et al.. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. Journal of Psychosomatic Research 2001;50:11-5. PII: S0022-3999(00)00210-5
26. Navarini, et.al. Analysis of Body Regions and Components of PASI Scores During Adalimumab or Methotrexate Treatment for Patients With Moderate -to-Severe Psoriasis.
J Drugs Dermatol 2014 May;13(5):554-62. doi: 10.36849/JDD.2020.4887
27.Reich K. and Christopher E. M. GriYths The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab. mini-review Arch Dermatol Res (2008) 300:537–544, DOI 10.1007/s00403-008-0885-7
28. S V Rakhesh, Mariette D'Souza, Ajith Sahai. Quality of life in psoriasis: a study from south India. Indian J Dermatol Venereol Leprol. 2008;Nov-Dec 2008,74(6):600-6:74(6):600-6. DOI:10.4103/0378-6323.45101

29. D,G,FORTUNE etal. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. British Journal of Dermatology. 1997;1997; 137: :755-60.
30. Yang et al.. The psoriasis disability index in Chinese patients: contribution of clinical and psychological variables. International Journal of Dermatology. 2005. International Journal of Dermatology2005,44, 925–929. Report
31. Shijun Li et.al.. The Role of Cellular Glutathione Peroxidase Redox Regulation in the Suppression of Tumor Cell Growth by Manganese Superoxide Dismutase. American Association for Cancer. 2000. CANCER RESEARCH 60, 3927–3939, July 15, 2000]
32.Sahib A.S. The Effects of Coq-10 Supplementation on Oxidative Stress and Inflammatory Markers in Iraqi Type 2 Diabetic Patients. 2016;4(5).
33.Kim J, Kim K, Sung GY. Coenzyme Q10 Efficacy Test for Human Skin Equivalents Using a Pumpless Skin-On-A-Chip System. Article, Int. J. Mol. Sci. 2020, 21, 8475; doi:10.3390/ijms21228475, www.mdpi.com/journal/ijms
34.Pagano et.al.. Current Experience in Testing Mitochondrial Nutrients in Disorders Featuring Oxidative Stress and Mitochondrial Dysfunction: Rational Design of Chemoprevention Trials. Review, International Journal of Molecular Sciences. 2014, 15, 20169-20208; doi:10.3390/ijms151120169.
35. Kharaeva et al.. Clinical and biochemical effects of coenzyme Q10, vitamin E, and selenium supplementation to psoriasis patients. Nutrition. 2009;25(3):295-302.
36.Saini R. Coenzyme Q10, Letters, The Essential Nutrient. J Pharm Bioallied Sci. 2011;3(3):466-7. E-mail: drperiodontist@yahoo.co.in
37. M.K.A. Basra,et.al The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results REVIEW ARTICLE, BJD British Journal of Dermatology, 2008 159, pp997–1035, DOI 10.1111/j.1365-2133.2008.08832.x
38. Revicki A,D,et.al. Relationship between Clinical Response to Therapy and Health-Related Quality of Life Outcomes in Patients with Moderate to Severe Plaque Psoriasis
Dermatology 2008;216:260–270 DOI: 10.1159/000113150